Eculizumab, the first approved treatment for patients with aHUS, is a humanized monoclonal complement inhibitor that binds to C5, preventing its cleavage to C5a and C5b and the subsequent activation of the complement terminal pathway (TP) and membrane attack complex (MAC) formation [6,7]. The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.